Total Payments
$995,238
2024 Payments
$242,345
Companies
27
Transactions
777
Medicare Patients
1,884
Medicare Billing
$343,650
Payment Breakdown by Category
Other$678,783 (68.2%)
Travel$143,892 (14.5%)
Consulting$127,106 (12.8%)
Food & Beverage$23,663 (2.4%)
Education$21,793 (2.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $601,037 | 177 | 60.4% |
| Travel and Lodging | $143,892 | 207 | 14.5% |
| Consulting Fee | $127,106 | 51 | 12.8% |
| Compensation for serving as faculty or as a speaker for a medical education program | $71,746 | 32 | 7.2% |
| Food and Beverage | $23,663 | 298 | 2.4% |
| Education | $21,793 | 8 | 2.2% |
| Honoraria | $6,000 | 4 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $350,005 | 195 | $0 (2024) |
| TESARO, Inc. | $220,386 | 211 | $0 (2019) |
| Eisai Inc. | $168,168 | 111 | $0 (2024) |
| Genmab U.S., Inc. | $83,293 | 39 | $0 (2024) |
| ABBVIE INC. | $80,629 | 63 | $0 (2024) |
| ImmunoGen, Inc. | $32,743 | 40 | $0 (2024) |
| Biom'Up France SAS | $23,069 | 25 | $0 (2021) |
| Intuitive Surgical, Inc. | $17,628 | 13 | $0 (2020) |
| Biom'Up SA | $6,182 | 12 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $3,784 | 11 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $242,345 | 169 | ABBVIE INC. ($80,613) |
| 2023 | $157,645 | 123 | Eisai Inc. ($62,218) |
| 2022 | $158,110 | 98 | GlaxoSmithKline, LLC. ($115,638) |
| 2021 | $114,091 | 70 | GlaxoSmithKline, LLC. ($107,456) |
| 2020 | $89,068 | 60 | GlaxoSmithKline, LLC. ($58,084) |
| 2019 | $139,977 | 142 | TESARO, Inc. ($127,673) |
| 2018 | $93,631 | 106 | TESARO, Inc. ($92,577) |
| 2017 | $371.59 | 9 | Genentech USA, Inc. ($146.70) |
All Payment Transactions
777 individual payment records from CMS Open Payments — Page 1 of 32
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,800.00 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | ELAHERE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,457.00 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | ELAHERE (Drug) | Travel and Lodging | In-kind items and services | $958.29 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $121.29 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | Eisai Inc. | Lenvima (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $3,150.00 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Eisai Inc. | Lenvima (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,312.50 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $124.74 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,275.00 | General |
| Category: Oncology | ||||||
| 12/05/2024 | ABBVIE INC. | ORILISSA (Drug) | Food and Beverage | In-kind items and services | $30.98 | General |
| Category: WOMENS HEALTH | ||||||
| 12/04/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $23.66 | General |
| Category: Diabetes | ||||||
| 12/03/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,800.00 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | Eisai Inc. | Lenvima (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $4,200.00 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Eisai Inc. | Lenvima (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,312.50 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $110.50 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Eisai Inc. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $48.00 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Eisai Inc. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $25.00 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $23.00 | General |
| Category: Oncology | ||||||
| 11/19/2024 | ABBVIE INC. | ELAHERE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,457.00 | General |
| Category: ONCOLOGY | ||||||
| 11/16/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $29.80 | General |
| Category: Biological | ||||||
| 11/14/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,250.00 | General |
| Category: Oncology | ||||||
| 11/14/2024 | ABBVIE INC. | ELAHERE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,257.00 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | ABBVIE INC. | ELAHERE (Drug) | Travel and Lodging | In-kind items and services | $588.99 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $122.17 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Travel and Lodging | In-kind items and services | $50.00 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 350 | 600 | $239,856 | $73,349 |
| 2022 | 15 | 463 | 735 | $258,426 | $84,147 |
| 2021 | 22 | 586 | 2,327 | $389,514 | $97,461 |
| 2020 | 21 | 485 | 2,534 | $306,445 | $88,692 |
Total Patients
1,884
Total Services
6,196
Medicare Billing
$343,650
Procedure Codes
70
All Medicare Procedures & Services
70 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 13 | 17 | $84,677 | $20,570 | 24.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 79 | 79 | $33,101 | $12,842 | 38.8% |
| 58571 | Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | Facility | 2023 | 18 | 18 | $54,108 | $12,585 | 23.3% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 13 | 17 | $10,846 | $7,033 | 64.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 65 | 104 | $15,010 | $6,590 | 43.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 28 | 63 | $13,671 | $5,949 | 43.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 21 | 27 | $7,425 | $3,556 | 47.9% |
| 86304 | Immunologic analysis for detection of tumor antigen, quantitative; ca 125 | Office | 2023 | 27 | 67 | $8,040 | $1,366 | 17.0% |
| 58100 | Biopsy of lining of uterus | Office | 2023 | 14 | 16 | $5,488 | $1,168 | 21.3% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 22 | 69 | $4,140 | $714.15 | 17.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 23 | 71 | $2,414 | $540.31 | 22.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 27 | 52 | $936.00 | $436.80 | 46.7% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2022 | 15 | 30 | $78,486 | $23,317 | 29.7% |
| 58571 | Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | Facility | 2022 | 22 | 22 | $66,132 | $16,166 | 24.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 68 | 68 | $28,492 | $12,056 | 42.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 57 | 109 | $23,653 | $11,012 | 46.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 36 | 40 | $11,000 | $5,716 | 52.0% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2022 | 17 | 20 | $12,760 | $5,292 | 41.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 39 | 57 | $8,208 | $3,901 | 47.5% |
| 86304 | Immunologic analysis for detection of tumor antigen, quantitative; ca 125 | Office | 2022 | 38 | 69 | $8,280 | $1,414 | 17.1% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 23 | 30 | $3,060 | $1,323 | 43.2% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 12 | 15 | $1,695 | $1,054 | 62.2% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 37 | 82 | $4,920 | $853.33 | 17.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 36 | 84 | $2,856 | $643.08 | 22.5% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Facility | 2022 | 19 | 19 | $6,460 | $619.19 | 9.6% |
About Dr. Heidi Godoy, DO
Dr. Heidi Godoy, DO is a Gynecologic Oncology healthcare provider based in Albany, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/09/2008. The National Provider Identifier (NPI) number assigned to this provider is 1427211366.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Heidi Godoy, DO has received a total of $995,238 in payments from pharmaceutical and medical device companies, with $242,345 received in 2024. These payments were reported across 777 transactions from 27 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($601,037).
As a Medicare-enrolled provider, Godoy has provided services to 1,884 Medicare beneficiaries, totaling 6,196 services with total Medicare billing of $343,650. Data is available for 4 years (2020–2023), covering 70 distinct procedure/service records.
Ad
Practice Information
- Specialty Gynecologic Oncology
- Location Albany, NY
- Active Since 07/09/2008
- Last Updated 05/03/2022
- Taxonomy Code 207VX0201X
- Entity Type Individual
- NPI Number 1427211366
Products in Payments
- ZEJULA (Drug) $481,665
- Lenvima (Drug) $167,771
- ELAHERE (Drug) $84,769
- Tivdak (Drug) $71,057
- JEMPERLI (Biological) $67,739
- Elahere (Biological) $28,557
- Da Vinci Surgical System (Device) $17,628
- HemoBlast Bellows (Device) $16,434
- TIVDAK (Drug) $12,236
- HEMOBLAST BELLOWS (Device) $7,053
- HEMOBLAST (Device) $5,791
- TIVDAK (Biological) $3,383
- Rubraca (Drug) $2,399
- SALVATION (Device) $807.45
- INFINITY (Device) $668.59
- Hemoblast (Device) $391.06
- Kerecis Omega3 SurgiClose (Device) $274.95
- LYNPARZA (Drug) $183.25
- Avastin (Biological) $146.70
- NAVIGATOR BIONAVIGATION SYSTEM (Device) $143.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gynecologic Oncology Doctors in Albany
Joyce Barlin, M.d, M.D
Gynecologic Oncology — Payments: $163,099
Gynecologic Oncology $163,099
Jovana Martin, Md, MD
Gynecologic Oncology — Payments: $2,558
Gynecologic Oncology $2,558
Patrick Timmins, M.d, M.D
Gynecologic Oncology — Payments: $2,011
Gynecologic Oncology $2,011
Dr. Tana Pradhan, D.o, D.O
Gynecologic Oncology — Payments: $854.94
Gynecologic Oncology $854.94
Benjamin Margolis, Md, MD
Gynecologic Oncology — Payments: $418.45
Gynecologic Oncology $418.45
Timothy Mcelrath, Md, MD
Gynecologic Oncology — Payments: $387.61
Gynecologic Oncology $387.61